Chimeric Therapeutics (ASX: CHM)

Currency in -

Last close As at 22/09/2023

-0.04

0.00 (0.00%)

Market capitalisation

22m

Latest Insights

Balance Sheet

Forecast net cash (A$m)

8.1

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (47.4) (45.9) (66.7)
Relative (46.7) (45.2) (67.3)
52 week high/low A$0.2/A$0.0

Financials

Edison Investment Research is terminating coverage on Chimeric Therapeutics (CHM). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (c) P/E (x) P/CF (x)
2020A 0.0 (0.1) (0.1) (6200.80) N/A N/A
2021A 0.0 (14.8) (14.9) (8.16) N/A N/A
2022E 0.0 (14.0) (14.0) (4.19) N/A N/A
2023E 0.0 (14.5) (14.5) (4.32) N/A N/A

Thematics

thematic

Industrials

The long and winding road

thematic

MediaWatch – July 2023

thematic

Consumer

ConsumerWatch – July 2023

thematic

Healthcare

ASCO 2023 key takeaways

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free